Clinical trial
Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer
NCT00083148 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00083148 |
|---|---|
| Title | Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer |
| Official title | Phase I Study of Irinotecan Followed by Capecitabine in Patients With Advanced Breast Carcinoma |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, irinotecan hydrochloride |
| Enrollment | 12 |
| Start date | Nov 1, 2002 |
| Primary completion | Mar 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | May 17, 2004 |
| Last update posted | Mar 9, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: